Cinacalcet 90 mg Tablets Recalled for Nitrosamine Impurity Above Safety Limits
Accord Healthcare is recalling Cinacalcet 90 mg tablets nationwide due to nitrosamine impurity (N-nitroso-cinacalcet) at levels exceeding the FDA's acceptable daily intake limit. The issue stems from manufacturing process deviations.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall involves a nitrosamine impurity exceeding the FDA's acceptable daily intake limit—a manufacturing quality issue with direct health risk implications. No illnesses or adverse events have been reported. This meets the High severity threshold as a risk-of-harm product without reported injury.
Plain-English summary
Accord Healthcare, Inc. is recalling Cinacalcet 90 mg tablets distributed nationwide in the United States and Puerto Rico. The recall affects two specific lots: Lot #M2303264 (expiration 01/2026) and Lot #M2306979 (expiration 04/2026). The tablets are manufactured by Intas Pharmaceuticals Limited in India for Accord Healthcare.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Testing identified N-nitroso-cinacalcet, a nitrosamine impurity, present at levels above the FDA's acceptable daily intake (ADI) limit. Nitrosamine impurities in pharmaceutical products require strict manufacturing controls to ensure patient safety.
Patients currently taking Cinacalcet from affected lots should contact their pharmacy or healthcare provider to verify whether their medication is part of this recall. Patients should not discontinue use without consulting their healthcare provider, as abrupt discontinuation could affect their medical condition. Affected medication should be returned to the pharmacy where it was dispensed. No adverse health events associated with this impurity have been reported to date.
The recalled product
- Product
- CINACALCET (CINACALCET)
- Brand
- CINACALCET
- Manufacturer
- ACCORD HEALTHCARE, INC.
- Category
- Drug — Prescription Medication
- Hazard
- nitrosamine
- manufacturing-defect
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CINACALCET
- HighCinacalcet prescription drug recalled for nitrosamine impurity and manufacturing deviations
FDA (Drugs) · 2026-04-22
- HighFDA Recalls Cinacalcet Tablets for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-04-22
- HighCinacalcet tablets recalled due to N-nitroso impurity above acceptable limits
FDA (Drugs) · 2026-04-22
- HighDrug Recall: Cinacalcet tablets contain excess nitrosamine impurity
FDA (Drugs) · 2025-12-17
- HighCinacalcet tablets recalled for nitrosamine impurity above acceptable limits
FDA (Drugs) · 2025-12-17
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27